Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH market and competition

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Apr 05, 2021 6:33pm

94 Views

Post# 32939100

RE:RE:RE:RE:RE:RE:RE:RE:RE:NASH market and competition

Good luck arguing on that here. Been there, done that...

it is like arguing against revealed truth...

jeffm34 wrote:
So are you saying that every single investor is wrong except for a handful of people posting on this board?

scarlet1967 wrote: Believe me I haven't missed that and it's real so is the reason why.

jeffm34 wrote:
You are missing the only thing that matters. The current share price the market has ascribed to TH's NASH program. It's not an oversight by investors. It's a reality.

scarlet1967 wrote: am I missing something here?